Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Fatigue

ClinicalTrials.gov lists 2,288 trials for Fatigue or a narrower condition beneath it. Radicle Science has the most among industry and government lead sponsors, with 14.

MeSH D005221 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 27 Phase 2 Phase 2 139 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 81 Phase 4 Phase 4 62 Not applicable Not applicable 1,469 Observational Observational 439 Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 27 Phase 2 Phase 2 139 Phase 2/3 Phase 2/3 31 Phase 3 Phase 3 81 Phase 4 Phase 4 62 Not applicable Not applicable 1,469 Observational Observational 439

Trials per phase (log scale)

2,065 of the 2,288 trials are tagged with Fatigue itself; the rest are tagged with a narrower condition beneath it.

Get the Fatigue report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Fatigue trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 224

1997: 2 trials (Phase 4 1, Phase 3 1) 1998: 1 trials (Not applicable 1) 1999: 4 trials (Observational 2, Phase 3 2) 2000: 3 trials (Phase 2 3) 2001: 5 trials (Observational 2, Not applicable 1, Phase 2 2) 2002: 15 trials (Not applicable 4, Phase 4 1, Phase 3 5, Phase 2 3, Phase 1 2) 2003: 19 trials (Observational 3, Not applicable 8, Phase 4 3, Phase 3 3, Phase 2 2) 2004: 15 trials (Observational 2, Not applicable 2, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 1, Phase 1 1) 2005: 31 trials (Observational 5, Not applicable 12, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 1) 2006: 34 trials (Observational 6, Not applicable 10, Phase 4 2, Phase 3 2, Phase 2/3 3, Phase 2 7, Phase 1/2 2, Phase 1 2) 2007: 38 trials (Observational 10, Not applicable 11, Phase 4 2, Phase 3 4, Phase 2/3 5, Phase 2 4, Phase 1/2 2) 2008: 56 trials (Observational 12, Not applicable 16, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 11, Phase 1/2 3, Phase 1 1) 2009: 57 trials (Observational 9, Not applicable 23, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 3, Phase 1 2) 2010: 61 trials (Observational 13, Not applicable 28, Phase 4 4, Phase 3 4, Phase 2/3 2, Phase 2 8, Phase 1 2) 2011: 55 trials (Observational 13, Not applicable 21, Phase 4 6, Phase 3 2, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 1) 2012: 57 trials (Observational 5, Not applicable 35, Phase 4 2, Phase 3 4, Phase 2 10, Phase 1 1) 2013: 58 trials (Observational 10, Not applicable 31, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2014: 77 trials (Observational 6, Not applicable 47, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 4, Phase 1 6) 2015: 54 trials (Observational 11, Not applicable 37, Phase 3 1, Phase 2/3 1, Phase 2 4) 2016: 71 trials (Observational 11, Not applicable 52, Phase 4 3, Phase 2 4, Phase 1/2 1) 2017: 92 trials (Observational 18, Not applicable 61, Phase 4 4, Phase 2/3 1, Phase 2 6, Phase 1 2) 2018: 95 trials (Observational 20, Not applicable 63, Phase 4 3, Phase 3 2, Phase 2 4, Phase 1/2 2, Phase 1 1) 2019: 107 trials (Observational 27, Not applicable 73, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2020: 101 trials (Observational 23, Not applicable 73, Phase 2 2, Phase 1/2 1, Phase 1 2) 2021: 165 trials (Observational 43, Not applicable 111, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2022: 187 trials (Observational 29, Not applicable 149, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 5) 2023: 206 trials (Observational 37, Not applicable 153, Phase 4 1, Phase 3 1, Phase 2 11, Phase 1/2 2, Phase 1 1) 2024: 191 trials (Observational 36, Not applicable 140, Phase 4 3, Phase 3 1, Phase 2/3 4, Phase 2 3, Phase 1 4) 2025: 224 trials (Observational 40, Not applicable 172, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 5, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 196
2025 224
2024 191
2023 206
2022 187
2021 165
2020 101
2019 107
2018 95
2017 92

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 230 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 188 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 1,508 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Fatigue trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 40
Phase 1/2 27
Phase 2 139
Phase 2/3 31
Phase 3 81
Phase 4 62
Not applicable 1,469
Observational 439

How many Fatigue trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 134
Recruiting 214
Enrolling by invitation 31
Active, not recruiting 68
Completed 1,381

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Fatigue trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Radicle Science 14

Which drugs are being tested for Fatigue? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Modafinil 23
METHYLPHENIDATE 17
Armodafinil 17
EPOETIN ALFA 7

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Exercise 28
Control (placebo) group 20
Acupuncture 10
Massage 9
citrate of caffeine 8

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Fatigue trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Diarrhea 61 5
Fatigue 54 8
Cough 31 1
ER Visit 26 1
Headache 26 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Fatigue? (4,087)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Social Isolation and Daily Steps Are Associated With Fatigue in Older Women With Cardiovascular Disease: A Secondary Analysis of the MindMoves Trial. Journal of aging and physical activity 2026 Yes
Protocol of a randomized trial of acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer. Contemporary clinical trials 2026 Yes
Feasibility and efficacy of peak-velocity interval training vs. moderate-intensity walking training in people with multiple sclerosis with severe fatigue and walking impairment: A pilot randomized controlled trial. Multiple sclerosis and related disorders 2026 Yes
Feasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT. Future oncology (London, England) 2026 Yes
Distinct Roles of Dopamine and Noradrenaline in Physical Fatigue. European journal of sport science 2026 Yes

Showing 5 of 4,087 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages